查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1877443

胎盤幹細胞療法市場：依療法類型、細胞類型、最終用戶、應用、國家和地區分類－全球產業分析、市場規模、市場佔有率及2025-2032年預測

Placental Stem Cell Therapy Market, By Therapy Type, By Cell Type, By End-user, By Application, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 355 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024 年胎盤幹細胞療法市場規模為 4.55 億美元，從 2025 年到 2032 年將以 18.5% 的複合年成長率成長。

胎盤幹細胞療法利用胎盤來源的幹細胞來治療神經系統疾病及其他疾病。市場的一個關鍵趨勢是日益重視再生醫學，強調幹細胞修復或取代受損神經元的能力，並滿足神經系統疾病領域尚未滿足的醫療需求。生物技術和幹細胞研究的進步正在加速市場成長。然而，監管方面的挑戰仍然是一大障礙，因為嚴格的核准流程可能會延遲產品上市並增加研發成本。此外，療法的高昂成本限制了其可及性，從而限制了患者的覆蓋範圍和整體市場擴張。

胎盤幹細胞療法市場—市場動態

技術進步與創新研究推動市場成長

技術進步和創新研究是胎盤幹細胞治療市場成長的關鍵驅動力。尖端技術改進了幹細胞的分離、處理和應用，從而提高了治療效率和安全性。例如，2023年11月，新加坡-麻省理工學院科研聯盟（SMART）旗下「個人化醫療製造關鍵分析」（CAMP）跨學科研究小組的研究人員，與新加坡科技研究局（ASTAR）生物加工技術研究院（BTI）和新加坡國立大學醫療系統（NUHS）合作，開發了一種直接從純骨髓穿刺液中提取了間質幹液（MSCs）的過程，從而簡化了間質幹液中提取間質幹液（MSCs）。這充分體現了研究突破如何推動市場成長。

胎盤幹細胞療法市場區隔分析：

全球市場按治療類型、細胞類型、最終用戶、應用和地區進行細分。

治療類型主要分為兩大類：異體療法和自體療法。異體療法因其「即用型」優勢而成為重要組成部分。這些源自捐贈者的細胞產品可以冷凍保存並立即使用，使其成為需要快速介入的緊急神經系統疾病治療的理想選擇。這種操作優勢省去了患者特異性（自體）細胞採集所需的時間和費用。全球監管重點也支持這一轉變；2023年，世界衛生組織批准了更新的人類細胞和組織療法全球原則，加強了成員國之間的品質、可追溯性和安全標準，並允許在臨床環境中更廣泛地應用異體細胞產品。此外，各國再生醫學政策正在加速其規模化應用；例如，日本藥品和醫療器材管理局（PMDA）在2022年至2024年間批准了20多項新的細胞和組織療法試驗，其中許多試驗採用了異體細胞庫系統來縮短生產時間。這些臨床和監管因素使異體胎盤幹細胞療法處於戰略地位，有助於市場成長。

從終端使用者角度來看，學術和研究機構在胎盤幹細胞療法的開發中發揮著至關重要的作用。他們的工作通常著重於了解胎盤來源間質幹細胞（MSCs）的生物學特性、安全性和治療潛力，以及製定良好生產規範（GMP）方案和在神經系統模型中評估其臨床前療效。一項發表於2024年《生物科學前沿》（Frontiers in Bioscience）的研究發現，人類胎盤來源的MSCs透過減少發炎和神經元凋亡，顯著改善了缺氧缺血性腦病大鼠模型的神經系統預後。

胎盤幹細胞療法市場—地域洞察

北美在胎盤幹細胞療法市場佔據顯著佔有率。該地區對胎盤幹細胞治療神經系統疾病潛力的認知不斷提高，推動了該療法的應用。患者對神經系統疾病替代療法的興趣日益濃厚，加上療法研發的進步，共同促進了市場成長。學術機構、醫療服務提供者和生物技術公司之間的合作，促進了專業設施的建立，提高了治療的可及性，並使胎盤幹細胞療法得以應用於神經系統疾病的臨床治療。

美國胎盤幹細胞療法市場—國家概況

美國在胎盤幹細胞療法治療神經系統疾病市場中扮演著舉足輕重的角色，這主要得益於阿茲海默症和帕金森氏症等與年齡相關的疾病日益普遍。預計到2050年，美國65歲以上人口中將有1,300萬人患有阿茲海默症，高於2025年的約720萬人。 2024年，近1,200萬美國人為失智症患者提供無償照顧，凸顯了有效療法的迫切需求。此外，近100萬美國人患有帕金森氏症，且罹病風險隨年齡增加而急劇增加。這些數據表明，人們對創新治療方案的需求日益成長，胎盤幹細胞療法已成為美國治療神經系統疾病的重要手段。

胎盤幹細胞療法市場－競爭格局：

胎盤幹細胞療法市場集中度適中，少數幾家關鍵企業引領創新並拓展全球業務。賽默飛世爾科技公司（Thermo Fisher Scientific, Inc.）、Cell Applications, Inc.、Bio-Techne 和 Cellular Engineering Technologies 等公司是專注於開發用於治療神經系統疾病和其他退化性疾病的先進幹細胞療法的領先企業。這些公司透過開發新的細胞分離、儲存和遞送技術來提高安全性、有效性和患者療效，從而展開競爭。例如，Pluristem Therapeutics 於 2024 年 2 月宣布與美國一家生物製藥公司建立策略合作夥伴關係，以推進胎盤來源間質幹細胞治療缺血性中風的臨床試驗，並迅速進入市場。持續的研發投入、與學術機構的合作以及促進產品商業化的法規核准，都有助於塑造市場競爭格局。為了滿足全球對再生療法日益成長的需求，企業擴張策略包括加強生產能力和進入新興市場。

目錄

第1章：胎盤幹細胞療法市集概覽

  • 研究範圍
  • 市場估算年份

第2章：執行概要

  • 市集
    • 胎盤幹細胞療法市場概覽（按療法類型分類）
    • 胎盤幹細胞療法市場概覽（按細胞類型分類）
    • 胎盤幹細胞療法市場按最終用戶分類的概況
    • 胎盤幹細胞療法市場按應用領域分類的概覽
    • 各國胎盤幹細胞療法市場概況
    • 胎盤幹細胞療法市場區域概覽
  • 競爭洞察

第3章：胎盤幹細胞療法主要市場趨勢

  • 胎盤幹細胞療法市場促進因素
    • 市場促進因素的影響分析
  • 胎盤幹細胞療法市場限制因素
    • 市場限制因素的影響分析
  • 胎盤幹細胞療法市場機遇
  • 胎盤幹細胞療法市場未來趨勢

第4章：胎盤幹細胞療法產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景分析
  • 規範架構分析

第5章：胎盤幹細胞療法市場：地緣政治緊張局勢升級的影響

  • 新冠疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：胎盤幹細胞療法市場概況

  • 胎盤幹細胞療法市佔率分析（2024年）
  • 主要製造商細分數據
    • 知名球員分析
    • 新興參與者分析

第7章：胎盤幹細胞療法市場－依療法類型分類

  • 概述
    • 按治療類型分類的細分市場佔有率分析
    • 異體療法
    • 自體療法

第8章：胎盤幹細胞療法市場－以細胞類型分類

  • 概述
    • 按細胞類型分類的細分市場佔有率分析
    • 間質幹細胞（MSCs）
    • 內皮祖細胞（EPCs）
    • 臍帶間質幹細胞
    • 造血幹細胞（HSCs）
    • 胎盤來源的間質幹細胞
    • 混合/共培養幹細胞

第9章：胎盤幹細胞療法市場－以最終用戶分類

  • 概述
    • 按最終用戶分類的細分市場佔有率分析
    • 醫院和專科診所
    • 研究與學術機構
    • 生物製藥公司
    • 合約研究組織（CRO）

第10章：胎盤幹細胞療法市場－依應用領域分類

  • 概述
    • 按細胞類型分類的細分市場佔有率分析
    • 血液系統惡性腫瘤和疾病
    • 代謝紊亂
    • 神經系統疾病
    • 先天性免疫缺乏疾病
    • 其他

第11章：胎盤幹細胞療法市場－以地域分類

  • 介紹
    • 按地域分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美胎盤幹細胞療法主要生產商
    • 北美市場規模及預測（按國家/地區分類）
    • 北美市場規模及預測（按治療類型分類）
    • 北美市場規模及預測（按電池類型分類）
    • 北美市場規模及預測（依最終用戶分類）
    • 北美市場規模及預測（按應用分類）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲胎盤幹細胞療法主要生產商
    • 歐洲市場規模及預測（按國家/地區分類）
    • 歐洲市場規模及預測（依治療類型分類）
    • 歐洲市場規模及預測（按電池類型分類）
    • 歐洲市場規模及預測（依最終用戶分類）
    • 歐洲市場規模及預測（按應用領域分類）
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 歐洲其他地區
  • 亞太地區
    • 概述
    • 亞太地區胎盤幹細胞療法主要生產商
    • 亞太市場規模及預測（依國家/地區分類）
    • 亞太地區市場規模及預測（依治療類型分類）
    • 亞太地區市場規模及預測（依細胞類型分類）
    • 亞太市場規模及預測（依最終用戶分類）
    • 亞太市場規模及預測（按應用分類）
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 亞太其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲胎盤幹細胞療法主要生產商
    • 拉丁美洲市場規模及預測（按國家/地區分類）
    • 拉丁美洲市場規模及預測（按治療類型分類）
    • 拉丁美洲市場規模及預測（按細胞類型分類）
    • 拉丁美洲市場規模及預測（按最終用戶分類）
    • 拉丁美洲市場規模及預測（按應用分類）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲（MEA）
    • 概述
    • 中東和非洲胎盤幹細胞療法主要生產商
    • MEA市場規模及預測（依國家/地區分類）
    • MEA市場規模及預測（依治療類型分類）
    • MEA市場規模及預測（依細胞類型分類）
    • MEA市場規模及預測（依最終用戶分類）
    • MEA市場規模及預測（依應用分類）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • 中東和非洲其他地區

第12章：主要供應商分析－胎盤幹細胞治療產業

  • 競爭基準化分析
    • Competitive Dashboard
    • Competitive Positioning
  • 公司簡介
    • Thermo Fisher Scientific, Inc
    • Cell Applications, Inc.
    • Bio-Techne
    • Cellular Engineering Technologies
    • AlloSource
    • STEMCELL Technologies, Inc.
    • PromoCell GmbH
    • Takara Holdings, Inc.
    • Lonza
    • Merck KGaA
    • Sartorius AG (CellGenix GmbH)
    • ATCC
    • AcceGen
    • Mesoblast Ltd
    • Others

第13章：360度AnalystView

第14章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV5748

The Placental Stem Cell Therapy Market size was valued at US$ 455 Million in 2024, expanding at a CAGR of 18.5% from 2025 to 2032.

Placental Stem Cell Therapy leverages placental-derived stem cells to treat neurological and other disorders. A key market trend is the growing emphasis on regenerative medicine, highlighting the ability of stem cells to repair or replace damaged neurons and address unmet medical needs in neurological conditions. Advances in biotechnology and stem cell research are accelerating market growth. However, regulatory challenges remain a significant barrier, as stringent approval processes can delay market entry and increase development costs. Additionally, the high cost of therapies limits accessibility, constraining patient reach and overall market expansion.

Placental Stem Cell Therapy Market- Market Dynamics

Technological Advances and Innovative Research Drive Market Growth

Technological advancements and innovative research are critical drivers of growth in the placental stem cell therapy market. Cutting-edge technologies improve the isolation, processing, and application of stem cells, thereby increasing treatment efficiency and safety. For instance, in November 2023, researchers from the Critical Analytics for Manufacturing Personalized Medicine (CAMP) Interdisciplinary Research Group (IRG) of Singapore-MIT Alliance for Research and Technology (SMART), in collaboration with ASTAR's Bioprocessing Technology Institute (BTI) and the National University Health System (NUHS), developed a technology to extract mesenchymal stem cells (MSCs) directly from pure bone marrow aspirate, streamlining. This demonstrates how research breakthroughs drive market growth.

Placental Stem Cell Therapy Market- Segmentation Analysis:

The worldwide market is segmented on the basis of Therapy Type, Cell Type, End-user, Application, and Region.

The therapy type segment is primarily divided into two groups Allogeneic Therapy and Autologous Therapy. Allogeneic therapies are an important segment due to their "off-the-shelf" availability. These donor-derived cell products can be cryopreserved and used right away, making them ideal for emergency neurological care where prompt intervention is required. This operational advantage eliminates the time and expense associated with patient-specific (autologous) cell harvesting. This shift is also being supported by global regulatory focuses; in 2023, the World Health Organization endorsed updated global principles for human cell and tissue therapies, strengthening quality, traceability, and safety standards across member states and allowing for broader deployment of allogeneic cell products in clinical settings. Furthermore, national regenerative-medicine policies are accelerating scale-up; for example, Japan's PMDA approved over 20 new cell- and tissue-based therapy trials between 2022 and 2024, many of which used allogeneic cell banking systems to reduce manufacturing time. These clinical and regulatory factors place allogeneic placental stem cell therapies in a strategic position to contribute to market growth.

Based on End user segment, Academic and research institutions play critical roles in the development of placental stem cell therapies. Their work frequently focuses on understanding the biology, safety, and therapeutic potential of placental-derived mesenchymal stromal cells (MSCs), as well as developing good manufacturing practices (GMP) protocols and preclinical efficacy in neurological models. A 2024 study published in Frontiers in Bioscience by a university-affiliated research center found that human placenta-derived MSCs significantly improved neurological outcomes in a rat model of hypoxic-ischemic encephalopathy by reducing inflammation and neuronal apoptosis.

Placental Stem Cell Therapy Market- Geographical Insights

North America has a significant market share for placental stem cell therapy. Adoption in the region is being driven by a growing awareness of placental stem cells' therapeutic potential for neurological conditions. Increased patient interest in alternative treatments for neurological disorders, combined with advances in therapy development, is driving market growth. Collaborations among academic institutions, healthcare providers, and biotechnology companies have facilitated the establishment of specialized facilities, increased accessibility and allowing clinical applications of placental stem cell therapies for neurological conditions.

United States Placental Stem Cell Therapy Market- Country Insights

The United States plays a pivotal role in generating revenue within the placental stem cell therapy market for neurological disorders, driven by the increasing prevalence of age-associated conditions such as Alzheimer's and Parkinson's disease. By 2050, it is projected that 13 million Americans aged 65 and older will be living with Alzheimer's, up from approximately 7.2 million in 2025. In 2024, nearly 12 million Americans provided unpaid care for individuals suffering from dementia, highlighting the urgent need for effective therapies. Additionally, nearly one million Americans are affected by Parkinson's disease, with risk increasing sharply with age. These statistics underscore the rising demand for innovative treatment options, positioning placental stem cell therapies as a significant therapeutic approach for managing neurological disorders in the U.S.

Placental Stem Cell Therapy Market- Competitive Landscape:

The placental stem cell therapy market is moderately concentrated, with a few key players driving innovation and expanding their global presence. Thermo Fisher Scientific, Inc., Cell Applications, Inc., Bio-Techne, and Cellular Engineering Technologies are among the leading companies that specialize in developing advanced stem cell therapies for neurological and other degenerative disorders. These companies compete by developing new cell isolation, storage, and delivery technologies that improve safety, efficacy, and patient outcomes. For example, Pluristem Therapeutics announced a strategic partnership with a biopharmaceutical company in the United States in February 2024 to advance clinical trials of placental-derived mesenchymal stem cells for ischemic stroke treatment, and to enter the market quickly. Continuous R&D investments, collaborations with academic institutions, and regulatory approvals that facilitate product commercialization all help to shape market competition. To meet the increasing global demand for regenerative therapies, expansion strategies include strengthening manufacturing capabilities and entering emerging markets.

Recent Developments:

In December 2024, Mesoblast Limited has announced that Ryoncil (remestemcel-L) has received FDA approval as the first mesenchymal stromal cell (MSC) therapy in the United States. Ryoncil is now the only MSC therapy approved in the United States, as well as the first treatment for steroid-resistant acute graft-versus-host disease (SR-aGvHD) in children as young as two months old, including adolescents and teenagers. Dr. Joanne Kurtzberg, a leading transplant physician at Duke University Medical Center, emphasized the importance of this approval, stating that Ryoncil provides a life-saving option for children with this severe condition, giving hope to both patients and their families.

In October, 2024, Aspen Neuroscience, Inc. has announced the expansion of its San Diego operations with a new 22,000 square foot facility dedicated to the GMP manufacturing of induced pluripotent stem cell (iPSC)-based therapies. This facility, located near the company's headquarters, will manufacture ANPD001, an iPSC-derived cell therapy for Parkinson's disease, as part of the ASPIRO trial. The expansion includes ISO-certified manufacturing suites, quality control labs, and more room for future growth and automation. Aspen is also working to industrialize autologous cell therapy manufacturing to improve throughput and streamline production processes.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL PLACENTAL STEM CELL THERAPY MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Thermo Fisher Scientific, Inc
  • Cell Applications, Inc.
  • Bio-Techne
  • Cellular Engineering Technologies
  • AlloSource
  • STEMCELL Technologies, Inc.
  • PromoCell GmbH
  • Takara Holdings, Inc.
  • Lonza
  • Merck KGaA
  • Sartorius AG (CellGenix GmbH)
  • ATCC
  • AcceGen
  • Mesoblast Ltd
  • Others

GLOBAL PLACENTAL STEM CELL THERAPY MARKET, BY THERAPY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Allogeneic Therapy
  • Autologous Therapy

GLOBAL PLACENTAL STEM CELL THERAPY MARKET, BY CELL TYPE- MARKET ANALYSIS, 2019 - 2032

  • Mesenchymal Stem Cells (MSCs)
  • Endothelial Progenitor Cells (EPCs)
  • Umbilical-Derived MSCs
  • Hematopoietic Stem Cells (HSCs)
  • Placental-Derived MSCs
  • Mixed/Co-Culture Stem Cells

GLOBAL PLACENTAL STEM CELL THERAPY MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals & Specialty Clinics
  • Research & Academic Institutes
  • Biopharmaceutical Companies
  • Contract Research Organizations (CROs)

GLOBAL PLACENTAL STEM CELL THERAPY MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Hematologic Malignancies and Disorders
  • Metabolic Disorders
  • Neurological Disorders
  • Congenital Immunodeficiency Disorders
  • Others

GLOBAL PLACENTAL STEM CELL THERAPY MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Placental Stem Cell Therapy Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Placental Stem Cell Therapy Market Snippet by Therapy Type
    • 2.1.2. Placental Stem Cell Therapy Market Snippet by Cell Type
    • 2.1.3. Placental Stem Cell Therapy Market Snippet by End-user
    • 2.1.4. Placental Stem Cell Therapy Market Snippet by Application
    • 2.1.5. Placental Stem Cell Therapy Market Snippet by Country
    • 2.1.6. Placental Stem Cell Therapy Market Snippet by Region
  • 2.2. Competitive Insights

3. Placental Stem Cell Therapy Key Market Trends

  • 3.1. Placental Stem Cell Therapy Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Placental Stem Cell Therapy Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Placental Stem Cell Therapy Market Opportunities
  • 3.4. Placental Stem Cell Therapy Market Future Trends

4. Placental Stem Cell Therapy Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Placental Stem Cell Therapy Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Placental Stem Cell Therapy Market Landscape

  • 6.1. Placental Stem Cell Therapy Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Placental Stem Cell Therapy Market - By Therapy Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Therapy Type, 2024 & 2032 (%)
    • 7.1.2. Allogeneic Therapy
    • 7.1.3. Autologous Therapy

8. Placental Stem Cell Therapy Market - By Cell Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Cell Type, 2024 & 2032 (%)
    • 8.1.2. Mesenchymal Stem Cells (MSCs)
    • 8.1.3. Endothelial Progenitor Cells (EPCs)
    • 8.1.4. Umbilical-Derived MSCs
    • 8.1.5. Hematopoietic Stem Cells (HSCs)
    • 8.1.6. Placental-Derived MSCs
    • 8.1.7. Mixed/Co-Culture Stem Cells

9. Placental Stem Cell Therapy Market - By End-user

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End-user, 2024 & 2032 (%)
    • 9.1.2. Hospitals & Specialty Clinics
    • 9.1.3. Research & Academic Institutes
    • 9.1.4. Biopharmaceutical Companies
    • 9.1.5. Contract Research Organizations (CROs)

10. Placental Stem Cell Therapy Market - By Application

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Cell Type, 2024 & 2032 (%)
    • 10.1.2. Hematologic Malignancies and Disorders
    • 10.1.3. Metabolic Disorders
    • 10.1.4. Neurological Disorders
    • 10.1.5. Congenital Immunodeficiency Disorders
    • 10.1.6. Others

11. Placental Stem Cell Therapy Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Placental Stem Cell Therapy Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Placental Stem Cell Therapy Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Placental Stem Cell Therapy Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Placental Stem Cell Therapy Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Placental Stem Cell Therapy Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Placental Stem Cell Therapy Industry

  • 12.1. Competitive Benchmarking
    • 12.1.1. Competitive Dashboard
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. Thermo Fisher Scientific, Inc
    • 12.2.2. Cell Applications, Inc.
    • 12.2.3. Bio-Techne
    • 12.2.4. Cellular Engineering Technologies
    • 12.2.5. AlloSource
    • 12.2.6. STEMCELL Technologies, Inc.
    • 12.2.7. PromoCell GmbH
    • 12.2.8. Takara Holdings, Inc.
    • 12.2.9. Lonza
    • 12.2.10. Merck KGaA
    • 12.2.11. Sartorius AG (CellGenix GmbH)
    • 12.2.12. ATCC
    • 12.2.13. AcceGen
    • 12.2.14. Mesoblast Ltd
    • 12.2.15. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us